Login to Your Account

Genexine releases early results for long-acting GH candidate GX-H9

By Haky Moon
Staff Writer

Thursday, September 8, 2016

HONG KONG – South Korean biotech firm Genexine Inc. (KOSDAQ:095700) recently released interim results for its second clinical trial of GX-H9, to treat growth hormone deficiency.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription